← All trials
NCT06135896
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 10, 2023
- Primary completion
- Jun 30, 2026
- Completion date
- Jun 30, 2026
- First posted
- Nov 18, 2023
- Last posted
- Nov 18, 2023
- Enrollment
- 98
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- National Cancer Center, KoreaLead sponsor
- National Cancer Center, KoreaReponsible party - principal investigator
- Seoul National UniversityCollaborator
- The National Cancer CenterOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.